PALVELLA THERAPEUTICS, INC. (PVLA) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 43 days, typically, give or take 24 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026before open 36 8-K
Q2 FY2026Tue, Aug 4, 2026before open 35 8-K
Q1 FY2026Thu, May 7, 2026before open 37 8-K
Q4 FY2025Tue, Mar 31, 2026before open 90 8-K
Q3 FY2025Mon, Nov 10, 2025after close 41 8-K
Q2 FY2025Thu, Aug 14, 2025before open 45 8-K
Q1 FY2025Thu, May 15, 2025before open 45 8-K
Q4 FY2024Mon, Mar 31, 2025before open 90 8-K

What they guided beta

Q3 FY2026 "Presented two posters at Fall Clinical Dermatology 2026 highlighting Phase 3 SELVA participant-reported clinical benefits and treatment satisfaction, as well as low and stable systemic rapamycin exposure over 24 hours, with mean exposure at least 40-fold lower than reported exposure with oral sirolimus." exhibit
Q3 FY2026 "Topline results from LOTU are expected in the second half of 2027." exhibit
Q3 FY2026 "Phase 2 trial initiation expected in the fourth quarter of 2026." exhibit
Q2 FY2026 "Palvella Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submitted to FDA, with completion of the NDA submission on track for the second half of 2026 Preparing for a planned standalone U.S. commercial launch of QTORIN™ rapamycin for microcystic lymphatic malformations in the first half of 2027, if approved Initiation of Phase 3 trial of QTORIN™ rapamycin for the treatment of cutaneous venous malformations planned for the fourth quarter of 2026 Initiation of" exhibit
Q2 FY2026 "The Company remains on track to complete the NDA submission in the second half of 2026." exhibit
Q2 FY2026 "Topline results from LOTU are expected in the second half of 2027." exhibit
Q2 FY2026 "Phase 2 trial initiation expected in the second half of 2026." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/PVLA
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/PVLA

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

PVLA earnings date badge

HTML

<a href="https://veritasdata.dev/company/PVLA/"><img src="https://veritasdata.dev/embed/PVLA.svg" alt="PVLA earnings date" width="240" height="56"></a>

Markdown

[![PVLA earnings date](https://veritasdata.dev/embed/PVLA.svg)](https://veritasdata.dev/company/PVLA/)

Script

<script async src="https://veritasdata.dev/embed/PVLA.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/PVLA"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.